HKeyBio Revolutionizes Drug Research with Launch of World's First NHP In Vitro Model HKeyBio has unveiled the pioneering HKEY-NHP-onChip™ 1.1, the first non-human primate model for autoimmune and allergic diseases, boosting research efficiency.

HKeyBio Revolutionizes Drug Research with Launch of World's First NHP In Vitro Model #China #Suzhou #Autoimmune_Diseases #HKeyBio #NHP_in_vitro_model

HotSpot Therapeutics Unveils Promising New IRF5 Inhibitor Data at European Lupus Meeting HotSpot Therapeutics recently shared exciting preclinical data for their new IRF5 inhibitor, showcasing its potential in treating autoimmune diseases at the European Lupus Meeting.

HotSpot Therapeutics Unveils Promising New IRF5 Inhibitor Data at European Lupus Meeting #United_States #Boston #Autoimmune_Diseases #HotSpot_Therapeutics #IRF5_Inhibitor

Repertoire Immune Medicines Partners with Lilly to Innovate Autoimmune Disease Therapies Repertoire Immune Medicines has teamed up with Eli Lilly to develop groundbreaking therapies for autoimmune diseases, aiming for effective treatments without general immune suppression.

Repertoire Immune Medicines Partners with Lilly to Innovate Autoimmune Disease Therapies #USA #Cambridge #Lilly #Autoimmune_Diseases #Repertoire_Immune

We Are ILL Wraps Up Successful Sixth Annual Wellness Weekend for Black Women with Autoimmune Diseases We Are ILL concluded its sixth Annual Wellness Weekend in Atlanta, empowering Black women with autoimmune diseases through community and education.

We Are ILL Wraps Up Successful Sixth Annual Wellness Weekend for Black Women with Autoimmune Diseases #USA #Atlanta #Black_Women #Autoimmune_Diseases #We_Are_ILL

Orna Therapeutics Showcases Promising In Vivo CAR Data at ASH Annual Meeting 2025 Orna Therapeutics shared compelling in vivo CAR program data targeting autoimmune diseases at the ASH Annual Meeting. Learn more about their innovative therapies.

Orna Therapeutics Showcases Promising In Vivo CAR Data at ASH Annual Meeting 2025 #USA #Watertown #Orna_Therapeutics #Autoimmune_Diseases #CAR_therapy

AbolerIS Pharma Reveals Breakthrough Research on New Antibody for Autoimmune Treatments AbolerIS Pharma recently published new preclinical findings on ABO21009, a pioneering anti-CD45RC antibody that shows promise in treating autoimmune diseases.

AbolerIS Pharma Reveals Breakthrough Research on New Antibody for Autoimmune Treatments #Belgium #Autoimmune_Diseases #AbolerIS_Pharma #ABO21009 #Gosselies

Orna Therapeutics to Present Key Findings on CAR Programs at ASH Annual Meeting Orna Therapeutics announces significant presentations on its in vivo CAR therapies targeting autoimmune diseases at the upcoming ASH Annual Meeting in Orlando.

Orna Therapeutics to Present Key Findings on CAR Programs at ASH Annual Meeting #USA #Orlando #Orna_Therapeutics #Autoimmune_Diseases #CAR_therapy

AbolerIS Pharma Welcomes Philippe Alen as Chief Business Officer to Drive Growth in Biopharmaceuticals AbolerIS Pharma announces the appointment of Philippe Alen as Chief Business Officer to lead strategic initiatives and enhance partnerships in the biopharmaceutical field.

AbolerIS Pharma Welcomes Philippe Alen as Chief Business Officer to Drive Growth in Biopharmaceuticals #Belgium #Autoimmune_Diseases #AbolerIS_Pharma #Gosselies #Philippe_Alen

RheumaGen Unveils Innovative HLA Gene-Editing Breakthrough at ACR Convergence 2025 RheumaGen, Inc. announced its revolutionary HLA gene-editing research at ACR Convergence 2025, targeting autoimmune diseases using anchor-position editing techniques.

RheumaGen Unveils Innovative HLA Gene-Editing Breakthrough at ACR Convergence 2025 #United_States #Aurora #RheumaGen #Autoimmune_Diseases #HLA_gene-editing

EVOQ Therapeutics Collaborates with Sanofi to Treat Autoimmune Diseases EVOQ Therapeutics has announced a significant collaboration with Sanofi, focusing on innovative treatments for autoimmune diseases using their proprietary NanoDisc technology.

EVOQ Therapeutics Collaborates with Sanofi to Treat Autoimmune Diseases #United_States #Chicago #Sanofi #Autoimmune_Diseases #EVOQ_Therapeutics

ImmunoVec Emerges from Stealth with Significant Funding for Innovative Autoimmune Disease Therapy ImmunoVec has launched its groundbreaking cell engineering platform, supported by a $40.7 million ARPA-H award, aimed at transforming treatments for autoimmune diseases.

ImmunoVec Emerges from Stealth with Significant Funding for Innovative Autoimmune Disease Therapy #USA #Los_Angeles #ARPA-H #Autoimmune_Diseases #ImmunoVec

Vie Ventures Launches Groundbreaking Therapeutics Council to Tackle Autoimmune Diseases Vie Ventures has successfully established its inaugural Therapeutics Advisory Council, fostering collaboration to accelerate treatments for autoimmune diseases through philanthropy and venture capital.

Vie Ventures Launches Groundbreaking Therapeutics Council to Tackle Autoimmune Diseases #USA #New_York #Autoimmune_Diseases #Vie_Ventures #Therapeutics_Advisory_Council

The Interleukin-23 Inhibitors Market Set for Significant Growth Between 2025 and 2034 The interleukin-23 inhibitors market is expected to grow substantially in the coming years, driven by rising autoimmune disease prevalence and advancements in targeted therapies.

The Interleukin-23 Inhibitors Market Set for Significant Growth Between 2025 and 2034 #None #Biologics #Autoimmune_Diseases #Interleukin-23

TYK2 Inhibitors Market Expected to See Robust Growth by 2034 with Expanding Drug Pipeline The TYK2 inhibitors market is set for tremendous growth by 2034, mainly due to the rising prevalence of autoimmune diseases and a strengthening drug pipeline.

TYK2 Inhibitors Market Expected to See Robust Growth by 2034 with Expanding Drug Pipeline #None #Autoimmune_Diseases #TYK2_inhibitors #drug_pipeline

Ouro Medicines Launches OM336 Study for Autoimmune Cytopenias with FDA Orphan Status Ouro Medicines has initiated a clinical study of OM336 for autoimmune cytopenias and received the FDA’s Orphan Drug Designation for AIHA.

Ouro Medicines Launches OM336 Study for Autoimmune Cytopenias with FDA Orphan Status #USA #San_Francisco #Ouro_Medicines #Autoimmune_Diseases #OM336

The Transformative Role of AVISE Testing in Diagnosing Autoimmune Diseases Like Lupus and RA Join an insightful webinar exploring how AVISE testing enhances diagnostic clarity for autoimmune diseases, improving patient outcomes.

The Transformative Role of AVISE Testing in Diagnosing Autoimmune Diseases Like Lupus and RA #Canada #Toronto #rheumatoid_arthritis #Autoimmune_Diseases #AVISE_Testing

Exploring the Impact of Massage Therapy on Autoimmune Disorders: AMTA's Research Findings The American Massage Therapy Association reveals emerging research on how massage therapy can benefit individuals with autoimmune diseases, enhancing quality of life and well-being.

Exploring the Impact of Massage Therapy on Autoimmune Disorders: AMTA's Research Findings #USA #Evanston #Massage_Therapy #AMTA #Autoimmune_Diseases

New Engineered Protein Could Revolutionize Treatment for Autoimmune Diseases Researchers developed an engineered protein that may provide a novel approach to treating autoimmune diseases like Type-1 diabetes and multiple sclerosis by targeting specific immune cells.

New Engineered Protein Could Revolutionize Treatment for Autoimmune Diseases #USA #New_York #Immunotherapy #Autoimmune_Diseases #Engineered_Protein

Surge in BAFF- and APRIL-targeted Therapies Amid Autoimmune Disease Rise The BAFF- and APRIL-targeted therapies market is booming due to the increasing incidence of autoimmune diseases and advances in treatment options, promising better outcomes.

Surge in BAFF- and APRIL-targeted Therapies Amid Autoimmune Disease Rise #無し #Autoimmune_Diseases #BAFF-targeted #APRIL-targeted

Orna Therapeutics Unveils Promising Preclinical Results for CAR Therapy Targeting Autoimmune Disorders Orna Therapeutics has revealed groundbreaking preclinical data at the ASGCT Annual Meeting, showcasing its innovative in vivo CAR therapy aimed at autoimmune diseases, highlighting potent findings that could transform treatment.

Orna Therapeutics Unveils Promising Preclinical Results for CAR Therapy Targeting Autoimmune Disorders #United_States #New_Orleans #Orna_Therapeutics #Autoimmune_Diseases #CAR_therapy

Projected Expansion of the Intravenous Immunoglobulin Market Through 2034 Amid Rising Autoimmune Disease Treatments The IVIG market is expected to see substantial growth by 2034 due to rising autoimmune diseases and advancements in biotechnology, highlighting innovative treatments.

Projected Expansion of the Intravenous Immunoglobulin Market Through 2034 Amid Rising Autoimmune Disease Treatments #United_States #Las_Vegas #biotechnology #Autoimmune_Diseases #IVIG_Market

Orna Therapeutics to Showcase Innovative CAR Therapy for Autoimmunity at Major Conference Orna Therapeutics is set to present its cutting-edge in vivo CAR therapy for autoimmune conditions at the prestigious ASGCT Annual Meeting, exhibiting its groundbreaking approach in gene therapy.

Orna Therapeutics to Showcase Innovative CAR Therapy for Autoimmunity at Major Conference #United_States #New_Orleans #Orna_Therapeutics #Autoimmune_Diseases #CAR_therapy

AliveDx Launches Innovative Multiplex Assay to Enhance Autoimmune Diagnostics AliveDx's new MosaiQ AiPlex CTDplus assay receives IVDR-CE mark, streamlining diagnostics for autoimmune rheumatic diseases across laboratories.

AliveDx Launches Innovative Multiplex Assay to Enhance Autoimmune Diagnostics #Switzerland #Autoimmune_Diseases #AliveDx #MosaiQ #Eysins

Silver Gene's Groundbreaking Genetic Solutions Debut at DxPx Conference Europe 2025 Discover how Silver Gene utilizes advanced genetic technology to tackle chronic symptoms and autoimmune diseases at the DxPx Conference 2025 in Düsseldorf.

Silver Gene's Groundbreaking Genetic Solutions Debut at DxPx Conference Europe 2025 #Germany #Düsseldorf #Silver_Gene #Genetic_Solutions #Autoimmune_Diseases